Migraine in Adolescents

Migraine Clinical Trial

Official title:

Migraine in Adolescents

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05654012
• Other study ID #: 202208056
• Status: Recruiting
• Phase: N/A
• Start date: June 1, 2023
• Est. completion date: March 15, 2030

Study information

• Verified date: August 2023
• Source: Washington University School of Medicine
• Contact: Alana McMichael, MA
• Phone: 314-273-6194
• Email: painlab[@]wustl.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Aim 1. To identify psychophysical and neural factors predicting migraine onset in adolescents

Aim 2a. To determine hormonal, psychophysical, and neural changes associated with migraine onset.

Aim 2b. To identify the temporal relationships between hormonal, psychophysical, and neural changes preceding vs. following migraine onset.

Aim 3. To identify psychophysical and neural factors predicting migraine prognosis in adolescents with migraine.

Description:

This study aims to identify predictors of migraine onset in adolescents as well as to determine hormonal, psychophysical, and neural changes associated with migraine onset. The study procedures involve an MRI scan, sensory testing, blood draw, meeting with a specialist to determine migraine diagnosis, and completing surveys

After signing the consent/assent form, participants and their parent/legal guardian will complete surveys to ensure eligibility. At the beginning and/or after the baseline study visit and the beginning and/or after the follow-up study visits, participants will meet (in person or via electronic communication) with a headache/ pain specialist or a trained study staff member to determine if they meet the criteria for migraine diagnosis (based on the International Classification of Headache Disorders, 3rd Edition (ICHD-3) criteria). Participants will receive a copy of the Migraine Physician Meeting Summary Form (Migraine Summary Form). This may be sent to their email directly, email via DocuSign or in person at a study visit. For the healthy group, participants are required not to meet the criteria for migraine at the baseline study visit. For the migraine group, participants are required to meet the criteria for migraine diagnosis or present with migraine symptoms at the baseline study visit. Participants will be asked to complete a one-hour MRI scan and a psychophysical session which will include quantitative sensory testing (QST) assessments of pain sensitivity and inhibitory pain modulation capabilities (by testing the conditioned pain modulation response). During the psychophysical session, participants may also complete demographic, pubertal, and other surveys. At the end of the study visit, a blood draw may be conducted and a saliva sample might be collected for analyses of sex hormone levels. For two days following each study visit, participants may be asked to complete saliva samples, preferably at the same time as the study visit, to assess sex hormone levels. Additional blood and/or saliva samples may be collected at the study visits and stored for future genetic, hormonal or immune analyses.

Participants will complete short online monthly surveys for 2 years asking about the number of headaches in the last month, headache severity, causes for the headaches (e.g., virus), additional symptoms, and any new migraine diagnosis.

After 1 and 2 years, participants will return for follow-up study visits which may include the same procedures (MRI session, psychophysical session, completing surveys and a blood draw, and meeting with a headache/ pain specialist/trained study staff member).

Post menarche participants may have a pregnancy test before initiation of the study visit procedures. In case of pregnancy, participants will only meet with the headache/ pain specialist/trained study staff member and complete surveys. In addition, for post-menarche participants, if possible, the follow-up study visits may be scheduled at the follicular phase of the menstrual cycle (1-10 days after the beginning of menstruation).

If participants meet the diagnosis criteria for migraine at the follow-up study visits, they may be asked to complete additional surveys regarding their headaches characteristics (e.g., headache duration, intensity, and treatments, following the NINDS Common Data Elements,[2] and migraine-related disability which is widely used in pediatric patients.[43; 44] 28 days before and/or after the baseline and follow-up study visits, participants may be asked to complete a daily headache diary to assess headache frequency.

All study procedures are optional and participates can stop or not complete tests if they want.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 250
• Est. completion date: March 15, 2030
• Est. primary completion date: March 15, 2028
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 10 Years to 13 Years

Eligibility

Inclusion criteria for healthy participants:

1. Age 10-13

2. Males or females (biological sex)

3. Not diagnosed with migraine or having migraine symptoms

4. With a first degree relative diagnosed with migraine (for the Fam-His group) or without a first or a second degree relative diagnosed with migraine (for the No-Fam-His group)

Inclusion criteria for participants with migraine:

1. Age 10-13

2. Males or females (biological sex)

3. Diagnosed with migraine or having migraine symptoms

4. Migraine duration > 6 months

5. Without preventative treatment or with stable preventative treatment for migraine (no change in intervention in the last 6 months)

Exclusion Criteria for the healthy group:

• Participants will not be enrolled if any of the following criteria exist and based on the investigator discretion:

1. Diagnosis of any chronic pain syndrome

2. Diagnosis of a neurological, developmental, pubertal, or psychiatric disorder

3. Taking pain or psychiatric medications regularly

4. Having an MRI contraindication such as metal in the body or claustrophobia

5. Not able to understand and communicate in English

Exclusion Criteria for the migraine group

• Participants will not be enrolled if any of the following criteria exist and based on the investigator discretion:

1. Diagnosis of any chronic pain syndrome other than migraine

2. Diagnosis of a neurological, developmental, pubertal, or psychiatric disorder

3. Having an MRI contraindication such as metal in the body or claustrophobia

4. Not able to understand and communicate in English

Related Conditions & MeSH terms

• Migraine
• Migraine Disorders

Intervention

Device:
• MRI
Grey Matter Volume (T1) Resting state BOLD
• Thermal Stimuli
The Thermal Sensory Analyzer (TSA-II or PATHWAY platform - Medoc, Ramat Yishai, Israel) will be used to safely deliver heat and cold stimuli. These devices can deliver relatively complex stimuli via computer control. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water container or a water bath (FISHER, USA). Participants will be free to pull out of the water bath at any time.
• Pressure stimuli
Pressure stimuli will be applied by using a handheld algometer (Wagner Instruments) or the Pressure Algometer (Medoc, Ramat Yishai, Israel). These devices have a round probe that allows quantifying the amount of pressure that is being applied. The Pressure Algometer allows a real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.

Behavioral:
• Pain ratings
Pain intensity and pain unpleasantness ratings will be assessed by numerical rating scale (ranging from 0- no pain/unpleasantness to- 10 or 100 the most intense/unpleasantness pain imaginable) and by mechanical and computerized visual analog scales (VAS which ranges between ''no pain sensation'' and ''most intense pain imaginable'').
• Pressure pain thresholds (PPT)
Pressure will be increased continually and participants will be instructed to press a button the first moment they feel pain from the pressure stimulus.
• Conditioned pain modulation (CPM) efficiency
The CPM paradigm assesses endogenous inhibitory pain modulation efficiency related to spatial filtering of nociceptive information.

Diagnostic Test:
• Hormonal assessment
Blood samples will be collected for analyses of sex hormone levels

Behavioral:
• Migraine-related measures
Adolescents with migraine will complete questions regarding their headache frequency and migraine symptoms.
• Neural assessments
MRI and fMRI scans

Diagnostic Test:
• Pubertal status
Pubertal status will be assessed using the self-reported Physical Developmental Scale-

Locations

Country	Name	City	State
United States	Washington University School of Medicine	Saint Louis	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
Washington University School of Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with a new diagnosis of migraine	Multivariable regression analyses with baseline psychophysical, and neural factors will be used to identify predictors for migraine diagnosis and headache frequency.; For Aim 1a, the primary outcome is migraine diagnosis (binary variable based on the physician's diagnosis), the independent variables are baseline PPT, CPM response, and FC of the right amygdala, and the controlling factors are race and age.	2 years
Primary	Number of participants with a new diagnosis of migraine	Multivariable regression analyses with baseline psychophysical, and neural factors will be used to identify changes related to migraine diagnosis.; For Aim 1b, the primary outcome measure is headache frequency (7-day average based on the headache diary completed before the 2-year follow-up visit), the independent variable is FC of the right amygdala, the controlling factors are the time of migraine diagnosis (at 1-year or 2-year study visit), race, and age. Since all participants will be at early pubertal maturation and pre-menarche at baseline, pubertal status will not be controlled for in this aim.	2 Years